About the Journal
OBJECTIVES & SCOPE
The Libyan International Journal of Oncology (LIJO) is dedicated to the worldwide advancement of oncology science, cancer research, education, and clinical practice. It is an informative monthly journal that addresses international issues relevant to a broad audience of cancer clinical specialists around the world, including but not limited to oncologists, cancer researchers, and policy makers.
LIJO's mission is to disseminate multidisciplinary clinical oncology and cancer research content that advances the state of knowledge, advances clinical practice, improves patient care, advocates for health policy change, and addresses global issues in oncology and cancer research.
LIJO welcomes high-quality, original surgical, clinical, translational, molecular, computational, in vivo, in vitro, and/or in silico studies, surgical reports, translational research, clinical trials, reviews, opinions, case reports, perspectives, and letters to the editor. Upon receipt, submissions are first reviewed by the LIJO Editorial Board for suitability to the journal's objective and scope, and then immediately subjected to a rigorous peer review process. Whenever possible, full protocols, procedures, and experimental details should be provided so that results can be reproduced.
The overall goal of the journal is to provide a multidisciplinary forum/hub that promotes clinical, surgical, pathophysiologic, molecular, translational, epidemiologic, behavioral, environmental, preventive, and/or educational implications that inform the complexity of cancer and help reduce the heavy burden on patients, their families, clinicians, scientists, the entire health care system, and society.
The journal's primary mission is to publish high-quality articles, including basic, translational, and clinical studies on all tumor types and using the latest medical, omics, digital, and/or computational technologies/approaches.
LIJO covers all areas of cancer research, including but not limited to aspects of oncology, molecular pathology, surgical oncopathology, genomics, epigenomics, metabolism, molecular biology, systems biology, cell signaling, bioinformatics, biomarker discovery, diagnosis, prognosis, prediction, drug discovery, immunology, targeted therapy, drug resistance, the microbiome, clinical trials, emerging (bio)technologies, environmental health, susceptibility studies, cancer prevention, epidemiology, education, and public health.
LIJO is the official journal of oncological science and cancer research published by the National Cancer Institute in Misurata, Libya.
Articles published in Libyan International Journal of Oncology are freely available under the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International License (CC BY). This license permits use, distribution, and reproduction in any medium, provided the original work is properly cited, not modified in any way, and not used for commercial purposes.
Publishing an article in a peer-reviewed journal is an essential model for the Libyan International Journal of Oncology . It is necessary to agree on standards for the expected ethical behavior of all parties involved in the publication: the author, the journal editor, the reviewer, and the publisher. Any manuscript or substantial portion thereof submitted to the journal may not be considered by any other journal. In general, the manuscript should not have been previously published in a journal or other citable form, even if deposited on a preprint server. Authors must ensure that no material submitted as part of a manuscript violates existing copyrights or the rights of third parties.
Open Access Policy
To ensure the widest possible dissemination of LIJO content, we have adopted an open access policy. This means that all articles published in LIJO are made freely available online in an easy-to-read format immediately after publication, without the need for subscription or registration. All published articles are licensed under a Creative Commons license.
Articles may be shared and adapted, provided attribution is given and the work is not used for commercial purposes. The journal also allows authors to self-archive the final accepted version of articles in an OAI-compliant institutional/subject repository.
Peer Review Policy
All manuscripts submitted to LIJO undergo a double-blind peer review process; the manuscript is reviewed by three experts in the respective field. The reports of all reviewers are considered in the decision to accept/revise or reject a manuscript. The Editor-in-Chief makes the final decision based on the reviewers' comments. The Editor-in-Chief may ask one or more Advisory Board members for their suggestions on accepting/revising or rejecting a manuscript before making the final decision. Associate editors and review editors provide administrative support to ensure the integrity of the peer review process. If authors challenge the editor's rejection decision with reasonable arguments, the manuscript may be referred to another reviewer upon whose recommendations the final decision is made.
All articles published in LIJO are released under a Creative Commons Attribution License CC International. The journal allows the author(s) to retain copyright to their work.
Authors' self-Archiving Policy.
The journal allows authors to archive pre-print, post-print, and publisher's version of articles in any OAI-compliant repository.
Authors should be mindful of the originality of their content when preparing a draft manuscript. If authors have used the work and/or words of others, they must be appropriately cited or quoted. All articles submitted to LIJO are checked for plagiarism using iThenticate (online plagiarism detection software). If plagiarism is detected during the review/editing process, the manuscript(s) will be rejected immediately. If plagiarism is discovered after publication, the manuscript will be withdrawn from the journal and an appropriate notice will be published. Depending on the severity of the case, we may also consider appropriate action against the authors.
Withdrawal from publication
We may bring such cases to the attention of the authors' funders, the authors' institutes (where they work), and the original authors whose work has been plagiarized. COPE Flowcharts will also be considered when handling plagiarism complaints.
Complaints and appeals
Authors and readers may email their complaints/appeals to the Editor-in-Chief or the Journal Editor. All complaints will be assigned a unique complaint number by the editor. Authors/readers may use the complaint numbers for further processing.
Neither the Libyan Journal of Oncology, nor its editors, nor the publisher, nor anyone else involved in the writing, production, or distribution assumes any liability or responsibility for the accuracy, completeness, or usefulness of the information contained in the journal, nor shall they be liable for any direct, indirect, incidental, special, or consequential damages arising out of the use of the Libyan Journal of Oncology.
Information For Readers
Information For Authors
Are you interested in submitting a paper to this journal? We encourage you to visit the About the Journal page to learn about the journal's policies and author guidelines. Authors must register with the journal before submitting papers. If you are already registered, you can simply log in and begin the five-step process.
Information For Librarians
We recommend that academic librarians add this journal to their library's electronic journal collection. Also, be aware that this journal's open-source publishing system is appropriate for libraries to make available to their faculty members for use with the journals they publish (see Open Journal Systems).